Urogen Pharma $URGN Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management significantly increased its stake in Urogen Pharma by 216.6%, owning approximately 9.46% of the company worth $48.2 million after acquiring an additional 2.98 million shares in the first quarter.
• Several analysts have given Urogen Pharma a consensus rating of "Buy", with target prices ranging from $16.00 to $36.00, and the average target price set at $32.00.
• In the latest quarter, Urogen Pharma reported a net loss of ($1.05) earnings per share (EPS), missing the consensus estimate, while the revenue was $24.22 million, exceeding analyst expectations.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 216.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,360,524 shares of the company's stock after acquiring an additional 2,983,368 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 9.46% of Urogen Pharma worth $48,227,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. CWM LLC increased its position in Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Urogen Pharma during the fourth quarter worth about $67,000. GAMMA Investing LLC increased its position in shares of Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after acquiring an additional 7,392 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Urogen Pharma during the fourth quarter worth about $137,000. Finally, Janus Henderson Group PLC bought a new stake in Urogen Pharma in the fourth quarter valued at about $149,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Piper Sandler began coverage on Urogen Pharma in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price for the company. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Guggenheim reiterated a "buy" rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Urogen Pharma presently has a consensus rating of "Buy" and an average target price of $32.00.

Urogen Pharma Stock Performance

URGN opened at $18.79 on Monday. The company has a fifty day moving average price of $18.19 and a two-hundred day moving average price of $12.90. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71. The firm has a market capitalization of $869.23 million, a PE ratio of -5.66 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Equities analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. This represents a 15.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,062 shares of company stock worth $465,115. 4.70% of the stock is owned by company insiders.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma (NASDAQ:URGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.